List of Excipients in Branded Drug ZOLPIMIST

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aytu BioPharma Inc	ZOLPIMIST	zolpidem tartrate	69654-510	BENZOIC ACID
Aytu BioPharma Inc	ZOLPIMIST	zolpidem tartrate	69654-510	CHERRY
Aytu BioPharma Inc	ZOLPIMIST	zolpidem tartrate	69654-510	CITRIC ACID MONOHYDRATE

Zolpimist Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 1, 2026

Zolpimist is a metered oral spray containing zolpidem tartrate, the active ingredient in immediate-release Ambien tablets. Its commercial differentiation comes from delivery format rather than novel pharmacology. The product uses a solvent-based oral spray system with ethanol and propylene glycol, sweetening and flavoring agents, acid-base control, and a metered pump.

The strongest current opportunities are reformulation, device redesign, supply-chain optimization, and lifecycle management. The original formulation patents provided historical protection but are no longer a durable barrier to generic or alternative oral-spray development.

What is Zolpimist and how does its formulation work?

Zolpimist is an oral spray indicated for the short-term treatment of insomnia characterized by difficulty initiating sleep. Each metered spray delivers 5 mg of zolpidem tartrate. The labeled dose is one or two sprays, equivalent to 5 mg or 10 mg of zolpidem tartrate, taken immediately before bedtime.[1]

The formulation is designed to dissolve zolpidem tartrate in a low-volume liquid vehicle and deliver the dose through a metered pump. The dosage form avoids tablet disintegration and swallowing, but it introduces formulation, device, taste, flammability, and dose-uniformity requirements.

Zolpimist formulation profile

Component	Functional role	Commercial relevance
Zolpidem tartrate	Active pharmaceutical ingredient	Immediate-release hypnotic
Ethanol	Solvent and penetration-enhancing vehicle	Supports drug solubility; creates flammability and labeling issues
Propylene glycol	Co-solvent and humectant	Supports solubilization and sprayability; may affect taste and tolerability
Sucralose	Sweetener	Masks bitterness from zolpidem and the solvent system
Citric acid and sodium citrate	Buffer system and pH control	Supports chemical stability and dose consistency
Peppermint flavor	Flavor masking	Improves acceptability of an alcohol-containing oral spray
Metered spray pump	Dose delivery system	Controls delivered volume and content uniformity

The FDA-approved labeling identifies alcohol, propylene glycol, sucralose, sodium citrate, citric acid, and peppermint flavor among the inactive ingredients.[1] The excipient list should be treated as part of the product's technical identity because changes can affect taste, spray plume, priming, delivered dose, microbial control, and stability.

What excipient strategy does Zolpimist use?

Zolpimist uses a volatile solvent and co-solvent platform. Ethanol provides high solvency and rapid evaporation. Propylene glycol helps maintain zolpidem tartrate in solution and moderates the physical behavior of the formulation during storage and spraying.

The combination has four formulation objectives:

1. Maintain zolpidem tartrate in a clear, stable solution.
2. Deliver a reproducible volume from each actuation.
3. Reduce the drug's bitter taste through sweetening and flavoring.
4. Produce rapid oral delivery without tablet disintegration.

The principal development constraint is the balance between solubility and patient acceptability. Increasing ethanol or propylene glycol can improve solubility but can worsen mouthfeel, burning, taste, and regulatory acceptability. Reducing those solvents can require pH adjustment, alternative co-solvents, complexation, or a different delivery architecture.

Key critical quality attributes

A competing Zolpimist formulation would need to control:

• Assay and degradation products
• Delivered dose per actuation
• Content uniformity across the container life
• Priming and repriming performance
• Spray pattern and droplet-size distribution
• Solution clarity and precipitation
• pH and buffer capacity
• Ethanol concentration
• Microbial quality
• Container-closure compatibility
• Taste and oral irritation
• Stability after repeated opening and use

For an oral spray, dose delivery is a combination-product issue even when the active formulation is chemically simple. The pump, actuator, dip tube, container, and closure system can materially affect the approved product.

What patents protect Zolpimist?

The original Zolpimist label identified U.S. Patent Nos. 6,635,678 and 7,074,430 as covering the product.[1] Those patents relate to zolpidem oral-spray technology and associated pharmaceutical compositions.

Patent	Product relevance	Approximate original term position
U.S. Patent No. 6,635,678	Oral pharmaceutical composition and spray delivery technology	Expiration period reached around 2020, subject to patent-term adjustment
U.S. Patent No. 7,074,430	Zolpidem oral-spray composition and delivery claims	Expiration period reached around 2022, subject to patent-term adjustment

The patents were important during the launch period because zolpidem itself was already an established active ingredient. Their value came from claiming the oral-spray formulation and delivery system rather than the underlying pharmacology.

The commercial implication is direct: the principal historical patent barrier has aged out. A new applicant can pursue an oral-spray zolpidem product without relying on the original sponsor's formulation patents, subject to current regulatory, trademark, device, and third-party patent analysis.

How strong is the Zolpimist patent estate?

The legacy estate is now weak as an exclusionary asset but remains relevant as technical prior art.

Its strength can be separated into four categories:

Asset category	Current strength	Reason
Zolpidem active-ingredient patents	None for commercial blocking	Zolpidem is an old, generic active ingredient
Original oral-spray composition patents	Low	Published patent terms have reached their ordinary expiration periods
Device and metering know-how	Moderate	Pump performance and dose uniformity remain difficult to replicate consistently
Trade secrets and manufacturing controls	Moderate	Solvent handling, filling, pump assembly, and stability data can create execution barriers

A new entrant could still obtain patents on a different solvent system, alcohol-free formulation, taste-masking approach, unit-dose package, or actuator geometry. Those patents would need meaningful technical differences and non-obviousness over the prior Zolpimist disclosures and the broader oral-spray literature.

What is the FDA regulatory and Orange Book status of Zolpimist?

Zolpimist was approved by the FDA under NDA 022036 in 2008 as an oral spray dosage form of zolpidem tartrate.[1] The product received regulatory protection as a new dosage form, not as a new chemical entity.

The likely regulatory protection structure was:

Protection type	Relevance to Zolpimist
New chemical entity exclusivity	Not available because zolpidem was already approved
Three-year approval exclusivity	Applicable to the new dosage form, generally running from approval in 2008
Pediatric exclusivity	No product-specific conclusion should be inferred without the current FDA exclusivity record
Orange Book patents	Original label-listed formulation patents were the relevant listings
REMS	Zolpidem products are subject to controlled-substance and safety requirements, but Zolpimist did not create a separate drug-class exclusivity platform

A generic version could potentially use an Abbreviated New Drug Application if it can satisfy the applicable product and bioequivalence requirements. Because Zolpimist is an oral spray rather than a conventional tablet, the regulatory pathway may require close attention to dosage form, delivered dose, pharmacokinetics, device performance, and comparative in vitro or clinical data.

When does Zolpimist lose exclusivity and what generic entry risks exist?

The meaningful market exclusivity period ended years ago. The three-year new-dosage-form exclusivity would have expired around 2011, while the cited formulation patents reached the end of their ordinary terms around 2020 to 2022.

The practical generic-entry timeline is therefore:

Period	Event
2008	FDA approval of Zolpimist under NDA 022036
Around 2011	End of likely three-year new-dosage-form exclusivity
Around 2020	Expiration period for U.S. Patent No. 6,635,678
Around 2022	Expiration period for U.S. Patent No. 7,074,430
Current market	Primary barriers are regulatory execution, device development, manufacturing, and commercial scale

What Paragraph IV challenges could affect Zolpimist?

A Paragraph IV challenge would be most relevant if an Orange Book-listed patent remained active or if a later patent covering a specific commercial formulation had been listed. The original formulation patents do not present a durable current barrier based on their published term dates.

A prospective ANDA applicant would still need to evaluate:

• Whether any current patent is listed against the NDA
• Whether a patent-term adjustment changes the expiration date
• Whether the proposed product uses the same reference-listed dosage form
• Whether the pump and actuator require a device-specific regulatory submission
• Whether the formulation is pharmaceutically equivalent
• Whether the applicant can demonstrate bioequivalence for a spray product
• Whether a 30-month stay or patent litigation risk is triggered by a certification

The principal litigation risk would likely arise from a new formulation or device patent, not from the basic zolpidem molecule.

What formulation patents could create new commercial protection?

A sponsor developing a next-generation zolpidem spray should focus on claims that solve measurable problems rather than broadly reciting ethanol, propylene glycol, and flavor.

Alcohol-free or low-alcohol formulations

An alcohol-free product could reduce flammability concerns, improve shipping and storage flexibility, and address patient acceptance. Candidate systems may include polyethylene glycol, glycerol, polysorbates, cyclodextrins, pH-controlled solubilization, or combinations of these materials.

The challenge is preserving rapid dissolution and consistent spray performance without increasing viscosity or causing precipitation.

Improved taste-masking systems

Zolpidem is bitter, and ethanol can create an additional sensory burden. Patentable approaches may include:

• Ion-pairing or complexation
• Cyclodextrin inclusion complexes
• Coated or suspended micro-particles
• pH-triggered release
• Alternative flavor systems
• Mucoadhesive taste-masking polymers
• Dual-chamber or sequential-delivery devices

The commercial value depends on demonstrated improvement in palatability without delaying onset.

Unit-dose and tamper-resistant packaging

Zolpidem is a Schedule IV controlled substance in the United States.[2] Unit-dose packaging, dose counters, tamper-evident closures, and limited-use actuators could reduce diversion and dosing errors.

Such protection may support differentiated prescribing and institutional use, although packaging patents alone rarely create a durable market moat.

Enhanced dose-control systems

A next-generation product could claim:

• Dose counters with lockout features
• Anti-drip actuators
• Orientation-independent delivery
• Automatic priming
• Low-residual-volume containers
• Metering systems with improved end-of-life accuracy
• Child-resistant and senior-friendly closures

Device claims may be commercially valuable when paired with formulation claims, especially if the device is necessary to achieve the labeled dose.

What commercial opportunities exist for Zolpimist excipients?

The strongest opportunity is a reformulated product that reduces the weaknesses of the original solvent-heavy formulation while retaining rapid onset.

Opportunity	Target improvement	Commercial rationale
Alcohol-free oral spray	Reduced flammability and improved tolerability	Broadens manufacturing and distribution options
Low-PG formulation	Better mouthfeel and lower irritation	May improve repeat use
Preservative-free multidose system	Cleaner excipient profile	Requires robust container-closure and microbial strategy
Unit-dose spray	Better control of abuse and dosing	Useful for institutional and caregiver settings
Premium taste-masked spray	Improved acceptability	Supports specialty positioning
Low-cost generic spray	Equivalent delivery at lower price	Targets existing oral-spray demand
Combination sleep product	Differentiated regimen	Carries added clinical and regulatory complexity
Pediatric or geriatric adaptation	Easier administration	Pediatric use faces substantial safety and labeling barriers

A reformulation sponsor should prioritize excipients with established oral-use precedents and a clear regulatory justification. Novel excipients increase development and review risk. The preferred strategy is usually an established excipient system with improved performance, supported by comparative stability, taste, and dose-delivery data.

How does Zolpimist compare with zolpidem tablets and sublingual products?

Attribute	Zolpimist	Immediate-release zolpidem tablet	Sublingual zolpidem product
Administration	Metered oral spray	Swallowed tablet	Placed under tongue
Swallowing required	No	Yes	No
Device dependency	High	Low	Low
Excipient complexity	Moderate to high	Low to moderate	Moderate
Solvent and taste burden	Material	Usually lower	Material but localized
Manufacturing complexity	Higher	Lower	Moderate
Patent differentiation	Formulation and device	Mostly legacy composition	Route and dosage-form claims
Generic development burden	Device and performance sensitive	Well-established	Route-specific
Patient segment	Patients seeking non-tablet administration	Broadest market	Patients needing rapid sublingual delivery

Zolpimist's advantage is administration without swallowing. Its disadvantage is the need to manage alcohol, flavor, pump performance, packaging, and controlled-substance handling.

Which companies are challenging Zolpimist commercially?

The competitive field includes:

• Generic manufacturers of zolpidem tablets
• Developers of sublingual zolpidem products
• Specialty pharmaceutical companies with oral-spray platforms
• Contract manufacturers with metered-dose liquid filling capabilities
• Device companies supplying oral spray pumps
• Companies developing digital adherence or controlled-dosing systems

The most credible threat is not necessarily a direct copy. A lower-cost tablet remains the dominant substitute, while a sublingual product can compete on rapid administration without the same pump and solvent burden.

A direct generic oral spray would face a smaller addressable market but could benefit from limited competition, established active-ingredient safety data, and lower drug-substance costs.

What manufacturing and intellectual-property barriers remain?

The manufacturing barriers are practical rather than molecule-specific.

Manufacturing issues

• Ethanol-safe production and storage
• Explosion-control systems
• Accurate low-volume filling
• Pump-component compatibility
• Extractables and leachables
• Container-closure integrity
• Long-term solvent loss
• Dose uniformity at beginning, middle, and end of container life
• Spray actuator reproducibility
• Stability under temperature excursions

The commercial winner may be the sponsor that achieves reliable device performance at scale rather than the sponsor with the most complex excipient system.

Geographic coverage

The U.S. patents identified in the product label do not establish global protection. Patent rights must be reviewed jurisdiction by jurisdiction, including Europe, Canada, Japan, Australia, and major emerging markets.

A global strategy should separate:

1. Expired composition patents.
2. Any surviving country-specific continuations or divisionals.
3. Device patents.
4. Manufacturing-process patents.
5. Trademark rights.
6. Regulatory data and market authorization rights.

The original U.S. estate should not be assumed to block development outside the United States, and U.S. expiration does not resolve foreign freedom-to-operate issues.

What litigation and settlement issues affect Zolpimist?

The core patent litigation risk has likely declined because the principal cited patents reached the end of their ordinary terms. The relevant current risks are:

• Patent litigation over a newly developed alcohol-free or taste-masked formulation
• Device patent disputes involving metered pumps
• Trade-secret claims involving formulation ratios or manufacturing methods
• Trademark disputes over the Zolpimist name
• ANDA litigation if a later-listed patent remains in the Orange Book
• Contract disputes involving licensing or distribution rights

No biosimilar pathway applies. Zolpimist is a small-molecule drug, so the relevant competitive mechanisms are ANDA approval, 505(b)(2) development, direct-to-market reformulation, and branded-generic substitution.

How should a sponsor value the Zolpimist opportunity?

The opportunity is strongest in three scenarios:

Low-cost generic oral spray

This strategy targets price-sensitive patients and payers. The sponsor should minimize excipient cost, use established pump components, and pursue a formulation that closely matches the reference product.

Premium next-generation spray

This strategy uses improved taste, lower alcohol content, unit-dose packaging, or a controlled-dosing actuator. It requires stronger clinical and human-factors evidence but may support specialty pricing.

Platform licensing

A company with oral-spray technology could license a formulation and device platform to a generic or specialty pharmaceutical company. The licensing package would be more valuable if it includes:

• Validated pump and actuator specifications
• Stability data
• Scale-up experience
• Human-factors data
• Regulatory correspondence
• Manufacturing know-how
• Freedom-to-operate analysis
• Patent filings on differentiated improvements

Revenue exposure for the original product is difficult to infer from public patent records alone. The commercial market is constrained by generic zolpidem tablets, controlled-substance prescribing limits, insomnia-treatment alternatives, and the absence of molecule-level exclusivity.

Key Takeaways

• Zolpimist is a 5 mg-per-spray oral formulation of zolpidem tartrate approved in 2008.
• Its excipient system uses ethanol, propylene glycol, sweetener, buffer components, and flavoring.
• The original product differentiation came from the oral-spray route and metered pump.
• U.S. Patent Nos. 6,635,678 and 7,074,430 were identified on the product label as relevant patents.
• The cited patent terms reached their ordinary expiration periods around 2020 to 2022.
• Current commercial protection depends more on device execution, manufacturing controls, regulatory data, and new improvement patents.
• The most attractive reformulation opportunities are alcohol-free delivery, improved taste masking, unit-dose packaging, and enhanced dose control.
• Zolpimist has no biosimilar pathway because zolpidem is a small-molecule active ingredient.
• A generic oral spray could face less competition than zolpidem tablets but would carry higher device and manufacturing complexity.
• The strongest new patent claims should focus on measurable technical improvements rather than the basic solvent-based oral-spray concept.

FAQs

Can Zolpimist be reformulated without ethanol?

Yes. An alcohol-free formulation could use alternative co-solvents, complexing agents, or pH-controlled solubilization. The sponsor would need to demonstrate solubility, stability, taste, spray performance, and bioequivalence or other applicable regulatory comparability.

Is propylene glycol essential to Zolpimist?

No. Propylene glycol is a formulation component that supports solubilization and physical performance. It could potentially be replaced, but the substitute must preserve clarity, dose uniformity, sprayability, stability, and patient acceptability.

Would a Zolpimist generic need the same spray pump?

Not necessarily. A generic applicant would need to meet the applicable requirements for pharmaceutical equivalence, delivered dose, device performance, and bioequivalence. A different pump may be used if it provides equivalent or acceptable performance.

Can a new taste-masked zolpidem spray receive patent protection?

Yes, if the taste-masking system provides a non-obvious technical benefit and is supported by comparative data. Broad claims covering ordinary sweeteners or flavors would face substantial prior-art risk.

Is Zolpimist suitable for a 505(b)(2) application?

A 505(b)(2) pathway could be relevant to a materially different zolpidem dosage form, formulation, device, or administration route. The appropriate pathway depends on the extent of reliance on the reference product and the new data required.

References

1. U.S. Food and Drug Administration. (2008). Zolpimist (zolpidem tartrate) oral spray prescribing information. NDA 022036.

2. U.S. Drug Enforcement Administration. (2024). Controlled substances alphabetical order. U.S. Department of Justice.

3. U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,635,678: Pharmaceutical compositions for oral administration.

4. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,074,430: Oral spray compositions containing zolpidem.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.